Skip to content

Rifampicin and pyrazinamide treatment for latent TB in HIV patients does not carry high risk of liver injury, but editorial still urges caution

UK government criticised for failure to act on TB

Prostate cancer more common in older HIV-positive men

Isoniazid prophylaxis halves risk of death for children with HIV in South Africa

Low risk of serious kidney toxicity on tenofovir, but mild renal dysfunction cause for concern

Efavirenz can be used at normal dose with rifampicin, Thais report

Detectable CMV predicts new AIDS events and deaths even with HAART

Evaluation of a new TB test highlights ongoing dilemmas of TB/HIV management

French IV drug users who report HAART side-effects have more risky sex